PRESS RELEASE

FOR IMMEDIATE RELEASE

PHARMANIAGA STRENGTHENS EARNINGS MOMENTUM AS Q2FY2026 NET PROFIT TRIPLES, DECLARES SECOND INTERIM DIVIDEND

Key takeaways:

- *Q2FY2026 revenue rose 12.3% to RM1.04 billion, while PAT more than tripled to RM13.0 million*
- *1HFY2026 revenue reached RM2.22 billion, with PAT up 31.2% to RM45.2 million*
- *Second interim dividend of 0.48 sen per share declared for FY2026*

SHAH ALAM, 13 AUGUST 2026 – Pharmaniaga Berhad (Pharmaniaga or the Group) delivered an encouraging set of financial results for the second quarter (Q2FY2026) and first half ended 30 June 2026 (1HFY2026), supported by higher order volumes under the Approved Products Purchase List (APPL), stronger sales to the private healthcare segment and lower finance costs.

For Q2FY2026, the Group recorded revenue of RM1.04 billion, representing a 12.3% increase from RM926.9 million recorded in the corresponding quarter of the previous financial year. Profit after tax (PAT) improved significantly to RM13.0 million, compared with RM4.2 million in Q2FY2025, while profit before zakat and taxation (PBT) increased to RM17.8 million from RM7.4 million previously.

For 1HFY2026, the Group recorded revenue of RM2.22 billion, up 12.0% from RM1.98 billion in the corresponding period last year. PAT increased 31.2% to RM45.2 million from RM34.5 million previously, reflecting ongoing improvement in the Group's operating performance and financial position.

The improved performance was underpinned by higher order volumes from Government hospitals under the APPL and stronger sales to the private healthcare segment. Supported by effective inventory management and the partial repayment of borrowings generated finance cost savings of RM7.0 million, further strengthening the Group’s profitability during the period.

For 1HFY2026, the Manufacturing Division remained a key earnings contributor, with earnings before interest, taxation, depreciation and amortisation increasing to RM55.6 million, compared with RM50.3 million in the corresponding period last year. The improvement was supported by stronger demand for the Group’s in-house manufactured products.

The Group also declared a second interim dividend of 0.48 sen per share for the financial year ending 31 December 2026, representing 50% of profit after tax and minority interest (PATAMI). The dividend will be paid on 13 October 2026, with the entitlement date set for 15 September 2026.

Pharmaniaga Managing Director, Dato' Zulkifli Jafar said, "Our first-half performance reflects the continued execution of our strategic priorities, underpinned by resilient demand across our core businesses, disciplined operational management and the growing contribution of our Manufacturing Division.

“These results reinforce the strength of our operating fundamentals as we build a more sustainable and resilient business for the long term. The Manufacturing Division continued to build on its positive trajectory during the quarter, supported by stronger demand for our in-house manufactured products.

“At the same time, our Logistics and Distribution business continued to play its critical role in supporting the national healthcare supply chain. Meanwhile, our Indonesia operations recorded healthy revenue growth.”

He added, "Looking ahead, we remain encouraged by the steady progress of our pharmaceutical and biopharmaceutical initiatives, particularly the localisation of strategic healthcare products that will strengthen Malaysia's supply security while supporting long-term margin enhancement.

"During the quarter, our vaccine localisation programme has marked significant milestones that brings us closer to commercialisation. We successfully completed the process validation batches for our Pneumococcal Conjugate Vaccine (PCV-13), while our manufacturing facilities underwent inspection by the National Pharmaceutical Regulatory Agency (NPRA) and were certified as compliant with Good Manufacturing Practice (GMP) requirements."

He continued, "Together with our expanding product pipeline and the recently secured RM281.7 million human insulin supply contract over three years, these initiatives reinforce our confidence in the Group's long-term growth prospects and our ability to create sustainability value for stakeholders.

"As we move into the second half of the year, we remain committed to strengthening operational excellence, enhancing our product portfolio and delivering quality healthcare products and solutions that meet the evolving needs of the nation. We will continue working closely with Ministry of Health Malaysia and our healthcare partners to ensure the resilience, efficiency and reliability of the national healthcare supply chain while creating sustainable value for our shareholders," he concluded.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the substantial shareholders of the Company. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit https://pharmaniaga.com/.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

For further media inquiries please contact:

Dato' Zuhri Iskandar Kamarzaman (Pharmaniaga)
E-mail: zuhri@pharmaniaga.com
Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)
E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993